Running interference: lumasiran and other RNA interference therapeutics for kidney diseases
Ziad A Massy1, Tilman B Drueke2
1Inserm Unit 1018, Team 5, Centre de recherche en épidémiologie et santé des populations (CESP), Hôpital Paul Brousse, Paris-Sud University (UPS) and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University, UVSQ), Villejuif, France; Department of Nephrology, Ambroise Paré University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Department of Nephrology, Boulogne-Billancourt/Paris, France.
No abstract available in PubMed .
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Chronic Kidney Disease III: Interprofessional Care
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
